Skip to main content
Premium Trial:

Request an Annual Quote

HiberGene Meningitis Test Gets CE Mark

NEW YORK (GenomeWeb) – Hibergene said last week that it has received CE marking for its HG Meningococcus Direct CSF test and launched it.

The test leverages loop mediated isothermal amplification technology and enables the rapid detection of Neisseria meningitidis, a leading cause of bacterial meningitis, directly from cerebrospinal fluid samples in less than 50 minutes. It can detect all known Neisseria meningitidis serogroups, including A, B, C, 29E, W135, X, Y, and Z at low levels with high accuracy, the Dublin-based firm said in a statement.

"HiberGene is building a portfolio of rapid molecular tests for a range of life-threatening diseases that are capable of saving lives and reducing healthcare costs," HiberGene CEO Brendan Farrell said in a statement, adding the development of the HG Meningococcus Direct CSF test "demonstrates how advances in technology can provide clinically important results in a matter of minutes to deliver significant improvements in patient care." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.